Accessibility Menu
Adc Therapeutics logo

Adc Therapeutics

(NYSE) ADCT

Current Price$1.27
Market Cap$160.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-95%
5 Year-94%
1 Year-58%
1 Month+16%
Adc Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.262026-07-20
Adc Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.8%USD 1.252026-07-13
1 month+15.6%USD 1.092026-06-18
3 month-69.34%USD 4.112026-04-21
Year to date-64.31%USD 3.532025-12-31
1 year-58.42%USD 3.032025-07-18
3 year-11.27%USD 1.422023-07-21
5 year-94.4%USD 22.512021-07-21
Since inception-95.45%USD 29.652020-05-15

Adc Therapeutics Financials at a Glance

Market Cap

$160.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$79.18M

Net Income (TTM)

-$136.99M

EPS (TTM)

-$1.05

P/E Ratio

-1.19

Dividend

$0.00

Beta (Volatility)

1.42 (Average)

Price

$1.27

Volume

6,505.058

Open

$1.33

Previous Close

$1.26

Daily Range

$1.26 - $1.40

52-Week Range

$0.78 - $4.98

Estimated Earnings Date

Aug 11, 2026

ADCT News

No articles available.

ADCT: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adc Therapeutics

ADC Therapeutics helps people fight tough cancers with specialized medicine. These treatments target and kill cancer cells while sparing healthy ones. This approach serves patients who have not found success with standard therapies.

Targeted Cancer Fighting Tools

  • ZYNLONTA: Medicine for adults with specific blood cancers that have returned; generated $20 million in revenue in Q1 2026.
  • Clinical Pipeline: Research programs testing new treatments for leukemia and various liquid or solid tumors.
  • Licensing and Royalties: Payments from partners selling the medicine outside the United States; brought in $0.8 million in Q1 2026.

Strategic Shifts and Partnerships

  • Approved a restructuring plan in June 2025 to focus on the best-selling medicine and prostate cancer programs.
  • Closed a research facility in the United Kingdom and reduced the global workforce by 30% in 2025.
  • Amended a royalty deal with HealthCare Royalty Management in February 2026 to change payment terms for control events.
  • Maintains development partnerships with groups like Genmab and Mitsubishi Tanabe Pharma Corporation to expand treatment reach.

What Makes Them Pioneers?

The company acts as a global pioneer in antibody drug conjugates, which combine antibodies with potent drugs to kill cancer. They successfully moved from a research startup to a commercial business with a product sold in major global markets.

Checking the Vital Signs

  • Total revenue reached $20.9 million in Q1 2026, down 9.5% from $23 million in Q1 2025.
  • Net loss narrowed to $33 million in Q1 2026, a 14.6% improvement from the previous year.
  • Operating income improved by 11.3% to a loss of $25.2 million in Q1 2026.
  • Cash and cash equivalents stood at $231 million as of March 31, 2026.

The Final Word

ADC Therapeutics has transitioned from a development-focused firm into a commercial-stage organization with a growing flagship product. Its recent restructuring efforts aim to focus resources on the most promising treatments for long-term sustainability.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

193

CEO

Ameet Mallik, MBA

Website

www.adctherapeutics.com

Headquarters

Epalinges, VD 1066, CH

ADCT Financials

Key Financial Metrics (TTM)

Gross Margin

90.71%

Operating Margin

-148.84%

Net Income Margin

-173.02%

Return on Equity

65.27%

Return on Capital

-42.81%

Return on Assets

-47.00%

Earnings Yield

-84.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$160.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

127.19M

Volume

6.51K

Avg. Volume

1.89M

Financials (TTM)

Gross Profit

$71.82M

Operating Income

-$117.84M

EBITDA

-$83.20M

Operating Cash Flow

-$114.55M

Capital Expenditure

-$45.77K

Free Cash Flow

-$114.59M

Cash & ST Invst.

$231.01M

Total Debt

$116.67M

Adc Therapeutics Performance Analysis

Adc Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 209,908,000518.9%
20232023-12-31USD 69,558,000-66.9%
20242024-12-31USD 70,837,0001.8%
20252025-12-31USD 81,357,00014.9%
Adc Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-18.2%
Q32025-09-30-12.8%
Q42025-12-3140.4%
Q12026-03-31-9.6%
Adc Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.01-32.9%
20232023-12-31USD -2.9446.1%
20242024-12-31USD -1.62-44.7%
20252025-12-31USD -1.12-30.9%
Adc Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-38.9%
Q32025-09-3040.0%
Q42025-12-3185.8%
Q12026-03-31-393.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$20.85M

-9.5%

Gross Profit

$17.24M

-17.8%

Gross Margin

82.66%

N/A

Market Cap

$160.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$852.45K

N/A

Employees

188

N/A

Net Income

-$32.97M

+14.6%

EBITDA

-$20.51M

+20.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$231.01M

+18.6%

Total Debt

$116.67M

-74.1%

Accounts Receivable

$31.05M

-2.3%

Inventory

$4.78M

-72.6%

Long Term Debt

$112.03M

-75.0%

Short Term Debt

$4.64M

+238.8%

Return on Assets

-47.00%

N/A

Return on Invested Capital

-52.64%

N/A

Free Cash Flow

-$29.74M

+47.5%

Operating Cash Flow

-$29.71M

+47.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QSIQuantum-Si incorporated
$0.82-0.66%
BCYCBicycle Therapeutics plc
$4.16-1.19%
NMRANeumora Therapeutics, Inc. Common Stock
$1.63+1.24%
AUTLAutolus Therapeutics plc
$1.40-2.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZYBTZhengye Biotechnology
$8.01+10.48%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$28.31+0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.68-0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.65+0.00%

Questions About ADCT

What is the current price of Adc Therapeutics?

Adc Therapeutics is trading at $1.26 per share.

What is the 52-week range for Adc Therapeutics?

Over the past 52 weeks, Adc Therapeutics has traded between $0.78 and $4.98.

How much debt does Adc Therapeutics have?

As of the most recent reporting period, Adc Therapeutics reported total debt of $116.67M.

How much cash does Adc Therapeutics have on hand?

Adc Therapeutics reported $231.01M in cash and cash equivalents in its most recent financial results.

What is Adc Therapeutics’s dividend yield?

Adc Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services